Research and Development Funding Expense (Details) $ in Thousands |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
|
Jun. 30, 2025
USD ($)
|
Jun. 30, 2024
USD ($)
|
Jun. 30, 2025
USD ($)
|
Jun. 30, 2024
USD ($)
|
Mar. 31, 2025
USD ($)
quarter
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Research and development funding expense | $ 300,500 | $ 500 | $ 351,000 | $ 1,000 | |
| Litifilimab | R&D Funding Arrangement With Biogen | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Unfunded R&D commitment | $ 150,000 | 150,000 | |||
| Daraxonrasib | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Research and development funding expense | $ 250,000 | ||||
| Biogen | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Aggregate payments | $ 250,000 | ||||
| Number of quarters | quarter | 6 | ||||
| Biogen | Litifilimab | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Upfront payment | $ 50,000 | ||||